Research Overview of S Citadep 20mg Tablets
S Citadep 20mg is a selective serotonin reuptake inhibitor (SSRI) manufactured by Cipla, containing escitalopram oxalate as the active pharmaceutical ingredient. This laboratory-grade compound is formulated for research applications investigating serotonin transporter mechanisms and neurochemical pathway modulation in controlled experimental conditions. Research scientists at Stroid UK Shop examine escitalopram’s selective binding properties at the serotonin transporter protein, contributing to understanding of monoamine neurotransmitter regulation in preclinical models.
Laboratory Research Applications
Escitalopram demonstrates high selectivity for the serotonin transporter (SERT) with minimal affinity for other neurotransmitter systems in binding assays. Laboratory investigations focus on its S-enantiomer configuration, which exhibits superior pharmacological activity compared to racemic citalopram in cell culture studies. Research protocols evaluate escitalopram’s influence on synaptic serotonin concentrations and downstream signaling cascades in neural tissue preparations. Studies within the broader escitalopram research category examine comparative SSRI mechanisms alongside investigations into selective androgen receptor modulators and peptide compounds for comprehensive pharmacological research programs.
Product Specifications
| Parameter | Specification |
|---|---|
| Active Ingredient | Escitalopram Oxalate |
| Strength | 20mg per tablet |
| Manufacturer | Cipla |
| CAS Number | 128196-01-0 (oxalate salt) |
| Molecular Formula | C₂₀H₂₁FN₂O·C₂H₂O₄ |
| Molecular Weight | 414.43 g/mol |
| Storage | Room temperature, dry conditions |
| Research Use | In-vitro studies only |
Laboratory Compliance Statement
S Citadep 20mg tablets are supplied exclusively for in-vitro research purposes and laboratory investigations. This pharmaceutical-grade compound is not intended for human consumption, therapeutic use, or any application outside controlled scientific research environments. Research facilities must maintain appropriate documentation and handling protocols when investigating escitalopram’s molecular mechanisms and pharmacological properties in experimental models.
